

Corrigendum

The affiliation of the authors Anker and von Haehling was rendered wrongly in the following papers: Morley et al. ¹, and Anker and von Haehling ², and for Anker and Springer in Toledo et al. ³, and Cvan Trobec et al. ⁴.

The correct affiliation is as given here:

Division of Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany.

References

1. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update. *J Cachexia Sarcopenia Muscle* 2014;**5**:253–9.
2. Anker SD, von Haehling S. Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention. *J Cachexia Sarcopenia Muscle* 2014;**5**:171–6.
3. Toledo M, Springer J, Busquets S, Tschirner A, López-Soriano FJ, Anker SD, Argilés JM. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. *J Cachexia Sarcopenia Muscle* 2014;**5**:315–20.
4. Cvan Trobec K, Kos MK, Trontelj J, Grabnar I, Tschirner A, Palus S, Anker SD, Springer J, Lainscak M. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. *J Cachexia Sarcopenia Muscle* 2015;**6**: 45–52.